multiple sclerosis treatment
The Food and Drug Administration has approved the drug fampridine-SR for the multiple sclerosis treatment. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease – and their efforts helped pave the way for today’s action by the FDA.”This is a good day for people who suffer from multiple sclerosis,” said Andrew Goodman, M.D., chief of the URMC Multiple Sclerosis Center. “Physicians will now have a new tool at their disposal that complements existing disease modifying therapies. For some patients, this Multiple Sclerosis Treatment drug will be a way to improve mobility and help regain some independence in their daily lives.”
Researchers at URMC helped develop the study protocols and lead the clinical trials that demonstrated consistently improved mobility – timed walking speed- in more than a third of patients with multiple sclerosis. This is the first instance in which a drug for multiple sclerosis treatment was found to improve function lost as a result of the disease. Goodman and his colleagues published the results of a Phase 3 clinical trial of the drug in the journal Lancet last February.Fampridine-SR is being developed by Acorda Therapeutics and marketed under the name Ampyra.
Multiple sclerosis is a disease of the central nervous system and is the most common cause of neurological disability in young adults with an estimated 2.5 million people worldwide suffering from the disease. Some of the most common symptoms are gait difficulties, muscle weakness, numbness or tingling in arms and legs, difficulty with coordination and balance, blurred vision, and slurred speech.These symptoms are triggered by attacks on cells in the central nervous system by the body’s own immune system. Specifically, these attacks damage cells called myelin which form the “insulation” around nerve fibers. When this insulation is damaged, communication in the central nervous system is delayed, disrupted, and even blocked. It is believed that fampridine improves the transmission of signals in the central nervous system of some multiple sclerosis patients by blocking potassium ion channels in nerve cells and restoring signal conduction.
Progress began to accelerate when the license to develop the drug was acquired by Acorda Therapeutics. The primary obstacle then was that the process of evaluating the drug’s impact required researchers to devise a new way to think about clinical trial methodology. Most Multiple Sclerosis Treatment drug are measured by their ability to prevent relapses or slow the progression of the disease, not reverse symptoms once they became established. Goodman and Schwid developed methods for assessing functional outcomes in multiple sclerosis patients such as measuring walking speed over a 25 foot distance.